SCHEMBL10043848

SCHEMBL10043848

Cc1cc2c(cn1)cc(-c1cc(NC(=O)Nc3cc(F)cc(C(F)(F)F)c3)ccc1C)c(=O)n2C

nearest known ligand 0.48

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
SYK P43405 1/20 0.48
KDR P35968 8/20 0.46
LCK P06239 3/20 0.46
JAK3 P52333 2/20 0.46
MAPK14 Q16539 2/20 0.46
TEK Q02763 1/20 0.46
PSEN1 P49768 1/20 0.42
PSEN2 P49810 1/20 0.42
APH1B Q8WW43 1/20 0.42
NCSTN Q92542 1/20 0.42
APH1A Q96BI3 1/20 0.42
PSENEN Q9NZ42 1/20 0.42
DDR2 Q16832 1/20 0.42
BRAF P15056 2/20 0.41
HTR2A P28223 2/20 0.40
HTR2C P28335 2/20 0.40
RIPK1 Q13546 2/20 0.40
RAF1 P04049 2/20 0.40
EIF2AK2 P19525 1/20 0.38
IDH1 O75874 1/20 0.38

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL10043847 0.90 SYK (0.59) SYKKDRLCKJAK3MAPK14
SCHEMBL13437918 0.89 SYK (0.56) SYKKDRLCKJAK3MAPK14
SCHEMBL10043839 0.87 SYK (0.47) SYKKDRLCKJAK3MAPK14
SCHEMBL10043845 0.86 SYK (0.45) SYKKDRLCKBRAFRIPK1
SCHEMBL10072021 0.85 SYK (0.59) SYKKDRLCKJAK3MAPK14
SCHEMBL10043860 0.84 SYK (0.51) SYKKDRLCKJAK3MAPK14
SCHEMBL10043828 0.84 RAB9A (0.48) SYKMAPK14BRAFRAF1NPC1
SCHEMBL10043846 0.83 KDR (0.49) SYKKDRLCKJAK3MAPK14
SCHEMBL10043821 0.82 SYK (0.49) SYKKDRLCKJAK3MAPK14
SCHEMBL10043855 0.82 SYK (0.43) SYKKDRLCKMAPK14BRAF

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8106068-B2 Compositions and methods for modulating c-kit and PDGFR receptors IRM LLC (BM) 2012-01-31 US disclosed
US-8106068-B2 Compositions and methods for modulating c-kit and PDGFR receptors IRM LLC (BM) 2012-01-31 US disclosed
US-20100081656-A1 COMPOSITIONS AND METHODS FOR MODULATING C-KIT AND PDGFR RECEPTORS IRM LLC (BM) 2010-04-01 US disclosed
US-20100081656-A1 COMPOSITIONS AND METHODS FOR MODULATING C-KIT AND PDGFR RECEPTORS IRM LLC (BM) 2010-04-01 US disclosed
US-7678792-B2 Compositions and methods for modulating c-kit and PDGFR receptors IRM LLC (BM) 2010-03-16 US disclosed
US-7678792-B2 Compositions and methods for modulating c-kit and PDGFR receptors IRM LLC (BM) 2010-03-16 US disclosed
US-20080176846-A1 COMPOSITIONS AND METHODS FOR MODULATING C-KIT AND PDGFR RECEPTORS IRM LLC (BM) 2008-07-24 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20080176846-A1 COMPOSITIONS AND METHODS FOR MODULATING C-KIT AND PDGFR RECEPTORS FYN, FLT3, SRC SYK 42/4885KDR 108/4885LCK 4/4885
US-20100081656-A1 COMPOSITIONS AND METHODS FOR MODULATING C-KIT AND PDGFR RECEPTORS FYN, FLT3, SRC SYK 42/4885KDR 108/4885LCK 4/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.